Ticagrelor

Ticagrelor, sold as Brilinta, is an antiplatelet medicine of the P2Y12 inhibitor class. The FDA label lists three uses: making cardiovascular death, heart attack and stroke less likely in people with acute coronary syndrome or a past heart attack; making a first heart attack or stroke less likely in people with coronary artery disease at high risk; and making a stroke less likely after an acute ischemic stroke (NIH Stroke Scale score of 5 or less) or a high-risk transient ischemic attack. The label carries a boxed warning that, like other antiplatelet agents, it can cause significant, sometimes fatal bleeding.

Also called BRILINTA

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 1116632; UNII GLH0314RVC; NDA022433, first approved on 2011-07-20 as a new molecular entity (Drugs@FDA record, sponsor ASTRAZENECA). The label read is the AstraZeneca label in openFDA (effective 2026-05-07); two repackager labels were not used. This page records label indications and the class only: no trial result is recorded for the medicine here, and no dose is given.

Trials at a glance

The figures count the 70 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
70
Phase 3 or 4
59
Recruiting
9
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseRecruitingCompletedTerminatedUnknown statusAll statuses
Phase 205027
Phase 2/302002
Phase 32131319
Phase 462011340
No phase10012
All phases94021970

Conditions these trials study

And 16 more.

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 52 more.

About this drug

Level
Substance
Mechanism
The label says ticagrelor and its major metabolite reversibly interact with the platelet P2Y 12 ADP-receptor to prevent signal transduction and platelet activation.

Claims and evidence

Context People for whom the US label of ticagrelor (Brilinta) lists an indication: acute coronary syndrome or past heart attack, high-risk coronary artery disease, acute ischemic stroke or high-risk transient ischemic attack

Recipient
Adult
Population
Patients described in the indications section of the label. The label does not state an age range in the passages read.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Follow-up
Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
Included
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of BRILINTA (ticagrelor), in the AstraZeneca version dated 7 May 2026 in openFDA, lists the medicine for lowering the chance of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also lists it for lowering the chance of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events, and for lowering the chance of stroke in patients with acute ischemic stroke (NIH Stroke Scale score of 5 or less) or a high-risk transient ischemic attack. The label carries a boxed warning that, like other antiplatelet agents, the medicine can cause significant, sometimes fatal bleeding.

    Applies to Adult People for whom the US label of ticagrelor (Brilinta) lists an indication: acute coronary syndrome or past heart attack, high-risk coronary artery disease, acute ischemic stroke or high-risk transient ischemic attack

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says it is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications and the first line of the boxed warning were read; contraindications, doses, interactions and other warnings were not recorded. Labels change: openFDA also lists repackager copies with older text. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (9)
    1. Supports openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.

      Locator
      results[0].indications_and_usage[0], 1.1, sentence 1, fragment 1 of 2
      How it applies
      First indication, first part.
      Retrieved
      Source effective date
      2026-05-07
      Source state
      Current
      Version fingerprint
      c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.

      Locator
      results[0].indications_and_usage[0], 1.1, sentence 1, fragment 2 of 2
      How it applies
      First indication, second part.
      Retrieved
      Source effective date
      2026-05-07
      Source state
      Current
      Version fingerprint
      c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.

      Locator
      results[0].indications_and_usage[0], 1.2, sentence 1, fragment 1 of 2
      How it applies
      Second indication, first part.
      Retrieved
      Source effective date
      2026-05-07
      Source state
      Current
      Version fingerprint
      c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.

      Locator
      results[0].indications_and_usage[0], 1.2, sentence 1, fragment 2 of 2
      How it applies
      Second indication, second part.
      Retrieved
      Source effective date
      2026-05-07
      Source state
      Current
      Version fingerprint
      c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Supports openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.

      Locator
      results[0].indications_and_usage[0], 1.3, sentence 1, fragment 1 of 2
      How it applies
      Third indication, first part.
      Retrieved
      Source effective date
      2026-05-07
      Source state
      Current
      Version fingerprint
      c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    6. Supports openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.

      Locator
      results[0].indications_and_usage[0], 1.3, sentence 1, fragment 2 of 2
      How it applies
      Third indication, second part.
      Retrieved
      Source effective date
      2026-05-07
      Source state
      Current
      Version fingerprint
      c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    7. Supports openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.

      Locator
      results[0].indications_and_usage[0], 1.3, parenthetical
      How it applies
      The stroke severity limit the label gives for the third indication.
      Retrieved
      Source effective date
      2026-05-07
      Source state
      Current
      Version fingerprint
      c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    8. Supports openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.

      Locator
      results[0].boxed_warning[0], sentence 1
      How it applies
      First line of the boxed warning.
      Retrieved
      Source effective date
      2026-05-07
      Source state
      Current
      Version fingerprint
      c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    9. Background openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260507.
      Retrieved
      Source effective date
      2026-05-07
      Source state
      Current
      Version fingerprint
      c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context United States approval record NDA022433 for Brilinta (ticagrelor)

Recipient
Recipient not specified
Population
Not stated in the fetched Drugs@FDA record. It names a product and a sponsor and gives no intended population or indication for the original approval.
Care setting
Not stated in the FDA record
Geography
United States (decision by the US Food and Drug Administration)
Life stage
Not stated in the FDA record
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (regulatory decision)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
Included
None stated
Excluded
None stated
  • Regulatory Evidence stage not applicable Certainty not assessed

    The openFDA Drugs@FDA record for New Drug Application NDA022433 (BRILINTA, ticagrelor tablets) lists the original approval as submission ORIG-1, with status date 20 July 2011, classified as Type 1 - New Molecular Entity, with standard review priority. The record names ASTRAZENECA as the sponsor of the application.

    Applies to Recipient not specified United States approval record NDA022433 for Brilinta (ticagrelor)

    Certainty method
    Not assessed
    Limitations
    This claim records the original approval and the fields the record gives. The record fetched carries no indication text for the original approval, so the claim does not say what the medicine was approved to treat in 2011; current uses are in the label claim. The record also lists many later supplements. An approval is not a finding about how well the medicine works. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (6)
    1. Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.

      Locator
      results[0].application_number
      How it applies
      The application number of this record.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
    2. Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.

      Locator
      results[0].submissions[14].submission_type
      How it applies
      The original submission.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
    3. Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.

      Locator
      results[0].submissions[14].submission_status_date
      How it applies
      The original approval status date, in compact form.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
    4. Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.

      Locator
      results[0].submissions[14].submission_class_code_description
      How it applies
      The submission classification of the original approval.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
    5. Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.

      Locator
      results[0].submissions[14].review_priority
      How it applies
      The review priority of the original approval.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.
    6. Supports openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.

      Locator
      results[0].sponsor_name
      How it applies
      The application sponsor, as the record writes the name.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). The raw record is committed in the atlas repository.

FDA label

Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for the products that contain this drug: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.

BRILINTA

Application
NDA022433
Labeler
AstraZeneca Pharmaceuticals LP
Label version
Version 56, effective
Label set id
f7b3f443-e83d-4bf2-0e96-023448fed9a8
Boxed warning
Yes
Sections the label has
Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA022433 BRILINTA
  2. Supplemental approval NDA022433 BRILINTA
  3. Supplemental approval NDA022433 BRILINTA
  4. Supplemental approval NDA022433 BRILINTA
  5. Supplemental approval NDA022433 BRILINTA
  6. Supplemental approval NDA022433 BRILINTA
  7. Supplemental approval NDA022433 BRILINTA

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 1

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 6 efficacy supplement approvals on record.

    ProductNDA022433

Registry trials 70

Record details

Record id
cardio:ticagrelor
Content hash
2d701f022832635cbab9f6e13c1c8e7dcc966ad31e8a1ecaeee1649df4f09f8d